GUFIC BIOSCIENCES
|
GUFIC BIOSCIENCES Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.22 | 9.89 | 4.56 | 2.34 | 2.82 |
| CEPS(Rs) | 10.52 | 11.84 | 6.24 | 3.77 | 3.42 |
| DPS(Rs) | 0.10 | 0.10 | 0.10 | 0.05 | 0.05 |
| Book NAV/Share(Rs) | 35.88 | 27.76 | 17.89 | 13.34 | 9.68 |
| Tax Rate(%) | 25.31 | 24.44 | 23.36 | 24.69 | 37.93 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.81 | 17.45 | 16.18 | 13.31 | 12.76 |
| EBIT Margin(%) | 14.35 | 15.59 | 13.75 | 11.25 | 12.63 |
| Pre Tax Margin(%) | 13.33 | 14.96 | 11.13 | 7.70 | 9.81 |
| PAT Margin (%) | 9.95 | 11.30 | 8.53 | 5.80 | 6.09 |
| Cash Profit Margin (%) | 12.74 | 13.53 | 11.67 | 9.34 | 7.38 |
| Performance Ratios | |||||
| ROA(%) | 11.54 | 20.98 | 10.00 | 5.65 | 8.04 |
| ROE(%) | 25.84 | 43.31 | 29.22 | 22.17 | 33.89 |
| ROCE(%) | 23.23 | 47.29 | 30.05 | 21.01 | 29.65 |
| Asset Turnover(x) | 1.16 | 1.86 | 1.17 | 0.98 | 1.32 |
| Sales/Fixed Asset(x) | 3.76 | 5.17 | 3.94 | 5.14 | 10.57 |
| Working Capital/Sales(x) | 4.55 | 6.31 | 5.35 | 11.67 | 7.81 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.27 | 0.19 | 0.25 | 0.19 | 0.09 |
| Receivable days | 81.36 | 59.40 | 81.43 | 97.98 | 93.16 |
| Inventory Days | 68.14 | 45.18 | 76.30 | 101.05 | 95.44 |
| Payable days | 167.52 | 124.89 | 184.25 | 227.30 | 173.92 |
| Valuation Parameters | |||||
| PER(x) | 22.70 | 25.18 | 25.05 | 20.15 | 26.98 |
| PCE(x) | 17.74 | 21.02 | 18.30 | 12.51 | 22.26 |
| Price/Book(x) | 5.20 | 8.97 | 6.39 | 3.53 | 7.86 |
| Yield(%) | 0.05 | 0.04 | 0.09 | 0.11 | 0.07 |
| EV/Net Sales(x) | 3.00 | 3.14 | 2.36 | 1.47 | 1.94 |
| EV/Core EBITDA(x) | 15.12 | 16.20 | 13.12 | 9.63 | 13.60 |
| EV/EBIT(x) | 18.05 | 18.51 | 16.12 | 12.66 | 14.99 |
| EV/CE(x) | 2.41 | 4.69 | 2.93 | 1.13 | 2.20 |
| M Cap / Sales | 2.62 | 3.10 | 2.27 | 1.21 | 1.69 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -11.36 | 59.76 | 28.74 | 8.00 | 14.79 |
| Core EBITDA Growth(%) | -9.20 | 72.42 | 51.37 | 15.45 | 20.44 |
| EBIT Growth(%) | -13.06 | 85.30 | 62.00 | -3.23 | 17.19 |
| PAT Growth(%) | -16.84 | 116.68 | 94.96 | 3.41 | 33.17 |
| EPS Growth(%) | -16.83 | 116.67 | 94.96 | -16.98 | 33.17 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.90 | 0.23 | 0.32 | 0.90 | 1.30 |
| Current Ratio(x) | 1.61 | 1.72 | 1.59 | 1.10 | 1.21 |
| Quick Ratio(x) | 0.97 | 1.10 | 1.02 | 0.73 | 0.78 |
| Interest Cover(x) | 13.98 | 24.64 | 5.23 | 3.17 | 4.48 |
| Total Debt/Mcap(x) | 0.17 | 0.03 | 0.06 | 0.32 | 0.17 |
Compare Financial Ratios of peers of GUFIC BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GUFIC BIOSCIENCES | ₹3,212.6 Cr | 8% | 8.7% | 57.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
GUFIC BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GUFIC BIOSCIENCES | 8% |
8.7% |
57.2% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
